Healthcare & Life Sciences

True North Therapeutics, Inc.

series-c-plus
series-c-plus
Stage
2
Investors

About

True North Therapeutics, Inc. develops humanized antibodies and novel biopharmaceutical therapies that inhibit the classical complement pathway to treat rare complement-mediated diseases in hematology, transplantation, and dermatology.

Explore True North Therapeutics, Inc.'s full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.